177 related articles for article (PubMed ID: 17656074)
1. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
[TBL] [Abstract][Full Text] [Related]
2. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Rosse RB; Mastropaolo J; Gaskins B
Clin Neuropharmacol; 2008; 31(1):34-9. PubMed ID: 18303489
[TBL] [Abstract][Full Text] [Related]
3. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
[TBL] [Abstract][Full Text] [Related]
4. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
Mastropaolo J; Rosse RB; Deutsch SI
Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637
[TBL] [Abstract][Full Text] [Related]
5. An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
J Psychopharmacol; 2023 Apr; 37(4):381-395. PubMed ID: 36927273
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.
Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
Neuropharmacology; 2007 Sep; 53(3):379-89. PubMed ID: 17632185
[TBL] [Abstract][Full Text] [Related]
7. Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
Int J Psychophysiol; 2019 Nov; 145():70-82. PubMed ID: 30790597
[TBL] [Abstract][Full Text] [Related]
8. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model.
Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
Neuropharmacology; 2007 Mar; 52(4):1179-87. PubMed ID: 17313962
[TBL] [Abstract][Full Text] [Related]
10. CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
Psychopharmacology (Berl); 2020 Dec; 237(12):3665-3687. PubMed ID: 32851421
[TBL] [Abstract][Full Text] [Related]
11. The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
Cannon CE; Puri V; Vivian JA; Egbertson MS; Eddins D; Uslaner JM
Neuropharmacology; 2013 Jan; 64():191-6. PubMed ID: 22659472
[TBL] [Abstract][Full Text] [Related]
12. CDP-choline: pharmacological and clinical review.
Secades JJ; Frontera G
Methods Find Exp Clin Pharmacol; 1995 Oct; 17 Suppl B():1-54. PubMed ID: 8709678
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic implications of a selective alpha7 nicotinic receptor abnormality in schizophrenia.
Deutsch SI; Rosse RB; Schwartz BL; Weizman A; Chilton M; Arnold DS; Mastropaolo J
Isr J Psychiatry Relat Sci; 2005; 42(1):33-44. PubMed ID: 16134405
[TBL] [Abstract][Full Text] [Related]
14. CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats: involvement of central nicotinic mechanism.
Uslu G; Savci V; Buyukuysal LR; Goktalay G
Neurosci Lett; 2014 May; 569():153-7. PubMed ID: 24708927
[TBL] [Abstract][Full Text] [Related]
15. Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: A pilot study.
Aidelbaum R; Labelle A; Baddeley A; Knott V
J Psychopharmacol; 2018 May; 32(5):541-551. PubMed ID: 29338621
[TBL] [Abstract][Full Text] [Related]
16. Expression of NR1, NR2A and NR2B NMDA receptor subunits is not altered in the genetically-inbred Balb/c mouse strain with heightened behavioral sensitivity to MK-801, a noncompetitive NMDA receptor antagonist.
Perera PY; Lichy JH; Mastropaolo J; Rosse RB; Deutsch SI
Eur Neuropsychopharmacol; 2008 Nov; 18(11):814-9. PubMed ID: 18674888
[TBL] [Abstract][Full Text] [Related]
17. CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression.
Knott V; Smith D; de la Salle S; Impey D; Choueiry J; Beaudry E; Smith M; Saghir S; Ilivitsky V; Labelle A
J Psychopharmacol; 2014 Dec; 28(12):1095-108. PubMed ID: 25315828
[TBL] [Abstract][Full Text] [Related]
18. Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease.
Park JE; Lee ST; Im WS; Chu K; Kim M
Neurosci Lett; 2008 Dec; 448(1):143-7. PubMed ID: 18938211
[TBL] [Abstract][Full Text] [Related]
19. Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent.
Deutsch SI; Rosse RB; Billingslea EN; Bellack AS; Mastropaolo J
Life Sci; 2003 Sep; 73(18):2355-61. PubMed ID: 12941437
[TBL] [Abstract][Full Text] [Related]
20. Indicators of neuroprotection with galantamine.
Geerts H
Brain Res Bull; 2005 Jan; 64(6):519-24. PubMed ID: 15639548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
